blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4190819

EP4190819 - PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  05.05.2023
Database last updated on 09.04.2026
FormerThe international publication has been made
Status updated on  16.09.2022
Most recent event   Tooltip27.03.2026New entry: Renewal fee paid 
Applicant(s)For all designated states
Akeso Biopharma Co., Ltd.
6 Shennong Road
Torch Development Zone
Zhongshan, Guangdong 528437 / CN
[2026/04]
Former [2024/37]For all designated states
Akeso Biopharma, Inc.
6 Shennong Road
Torch development Zone
Zhongshan, Guangdong 528437 / CN
Former [2023/23]For all designated states
Akeso Biopharma, Inc.
6 Shennong Boulevard
Torch developmental Zone
Zhongshan, Guangdong 528437 / CN
Inventor(s)01 / WANG, Zhongmin
Zhongshan, Guangdong 528437 / CN
02 / LI, Baiyong
Zhongshan, Guangdong 528437 / CN
03 / XIA, Yu
Zhongshan, Guangdong 528437 / CN
 [2023/23]
Representative(s)Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
[N/P]
Former [2023/23]Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
Application number, filing date22766354.910.03.2022
[2023/23]
WO2022CN80107
Priority number, dateCN20211027065212.03.2021         Original published format: CN202110270652
[2023/23]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022188832
Date:15.09.2022
Language:ZH
[2022/37]
Type: A1 Application with search report 
No.:EP4190819
Date:07.06.2023
Language:EN
[2023/23]
Search report(s)International search report - published on:CN15.09.2022
(Supplementary) European search report - dispatched on:EP12.07.2024
ClassificationIPC:C07K16/46, C07K16/30, A61K39/395, A61P35/00
[2023/23]
CPC:
A61P35/00 (EP,CN,IL,KR,US); A61K39/39533 (KR); A61K39/3955 (CN);
A61K39/39558 (US); A61K31/337 (EP); A61K31/502 (EP,KR);
A61K31/5025 (US); A61K31/519 (EP,KR); A61K31/555 (EP);
A61K31/7048 (EP); A61K31/7068 (EP,KR); A61K39/395 (EP,IL);
A61K39/39541 (US); A61K45/06 (EP,CN,IL,KR); C07K16/22 (EP,CN,KR,US);
C07K16/2818 (EP,CN,KR,US); C07K16/30 (IL); C07K16/46 (IL);
A61K2039/505 (EP,KR); A61K2039/545 (EP,KR); A61K2300/00 (KR,US);
C07K2317/21 (EP); C07K2317/31 (EP,CN,KR,US); C07K2317/52 (CN);
C07K2317/56 (CN); C07K2317/565 (CN); C07K2317/622 (EP,CN,KR);
C07K2317/71 (EP); C07K2317/732 (EP,KR,US); C07K2317/734 (EP,US);
C07K2317/76 (CN); C07K2317/92 (EP,CN,KR,US) (-)
C-Set:
A61K31/337, A61K2300/00 (EP);
A61K31/502, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP);
A61K31/555, A61K2300/00 (EP);
A61K31/7048, A61K2300/00 (EP);
A61K31/7068, A61K2300/00 (EP);
A61K39/3955, A61K2300/00 (CN);
A61K39/395, A61K2300/00 (EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/23]
Extension statesBA03.03.2023
ME03.03.2023
Validation statesMD03.03.2023
TitleGerman:PHARMAZEUTISCHE KOMBINATION MIT BISPEZIFISCHEM ANTI-PD-1-ANTI-VEGFA-ANTIKÖRPER UND VERWENDUNG DAVON[2023/23]
English:PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF[2023/23]
French:COMBINAISON PHARMACEUTIQUE CONTENANT UN ANTICORPS BISPÉCIFIQUE ANTI-PD-1-ANTI-VEGFA, ET SON UTILISATION[2023/23]
Entry into regional phase03.03.2023Translation filed 
03.03.2023National basic fee paid 
03.03.2023Search fee paid 
03.03.2023Designation fee(s) paid 
03.03.2023Examination fee paid 
Examination procedure03.03.2023Examination requested  [2023/23]
30.01.2025Date on which the examining division has become responsible
14.02.2025Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
14.04.2025Amendment by applicant (claims and/or description)
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
14.04.2025Request for further processing filed
14.04.2025Full payment received (date of receipt of payment)
Request granted
16.04.2025Decision despatched
Fees paidRenewal fee
02.02.2024Renewal fee patent year 03
26.03.2025Renewal fee patent year 04
26.03.2026Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y] CN109053895  (AKESO BIOPHARMA INC et al.) [Y] 1-16 * throughout, e.g. [0031]-[0068], [0081] *
 [A] CN110960543  (ANHUI RUBIOX VISION BIOTECHNOLOGY CO LTD et al.) [A] 1-16 * the whole document *
 [A] WO2021026685  (ANHUI BIOX VISION BIOLOGICAL TECH CO LTD et al.) [A] 1-16 * Example 1 *
 [A] US2021040193  (YANG YAPING et al.) [A] 1-16 * Examples 4, 10 *
 [Y]   VIKAS PRAVEEN ET AL: "Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors", FRONTIERS IN ONCOLOGY, vol. 10, 28 April 2020 (2020-04-28), XP093141125, ISSN: 2234-943X, DOI: 10.3389/fonc.2020.00570 [Y] 1-16 * Abstract, Tables 1-5 *

DOI:   http://dx.doi.org/10.3389/fonc.2020.00570
 [Y]   VINAYAK SHAVETA ET AL: "Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer", JAMA ONCOLOGY, vol. 5, no. 8, 1 August 2019 (2019-08-01), US, pages 1132, XP055828340, ISSN: 2374-2437, DOI: 10.1001/jamaoncol.2019.1029 [Y] 1-16 * Abstract, Discussion *

DOI:   http://dx.doi.org/10.1001/jamaoncol.2019.1029
 [Y]   MEGAN LO ET AL: "Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 292, no. 9, 11 January 2017 (2017-01-11), US, pages 3900 - 3908, XP055428854, ISSN: 0021-9258, DOI: 10.1074/jbc.M116.767749 [Y] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M116.767749
 [T]   ANONYMOUS CHUNG YING ET AL: "PARP Inhibitors in Cancer Diagnosis and Therapy | Clinical Cancer Research | American Association for Cancer Research", CLINICAL CANCER RESEARCH, vol. 27, no. 6, 15 March 2021 (2021-03-15), US, pages 1585 - 1594, XP093179432, ISSN: 1078-0432, Retrieved from the Internet DOI: 10.1158/1078-0432.CCR-20-2766 [T]

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-20-2766
International search[PY] CN112830972  (AKESO BIOPHARMA INC et al.) [PY] 1-29 * claims 1-22 *
 [Y] CN109053895  (AKESO BIOPHARMA INC et al.) [Y] 1-29 * claims 1-23, and description, paragraphs 22-168 *
 [Y] CN112300286  (AKESO PHARMACEUTICALS INC et al.) [Y] 1-29 * claims 1-28 *
 [Y] CN110831580  (TESARO INC et al.) [Y] 1-29 * claims 46-93 *
 [A] WO2019152642  (MERCK SHARP & DOHME et al.) [A] 1-29 * entire document *
 [A]   CUI YU-HENG, SHAO-RONG ZHAO, LIU JING-JING, JIN ZHANG: "Research Progress of PD-1/PD-L1 Inhibitors Combined with Other Immune Checkpoint Inhibitors in the Treatment of Triple Negative Breast Cancer", TIANJIN MEDICAL JOURNAL, vol. 48, no. 12, 31 December 2020 (2020-12-31), pages 1230 - 1235, XP055966276, DOI: 10.11958/20200705 [A] 1-29 * pp. 1230-1235 *

DOI:   http://dx.doi.org/10.11958/20200705
 [A]   GHONIM MOHAMED A, TARHUNI ABDELMETALAB, LUU HANH, DEAN MATTHEW, ALKHAMI AMIR, OCHOA AUGUSTO, BOULARES HAMID: "Low Doses of PARP Inhibitors As A novel Therapeutic Approach to Enhance The AntiCancer Immunotherapy of PD1 Immune Checkpoint Blockade", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 33, no. S1, 1 April 2019 (2019-04-01), US, pages 680.15, XP009539485, ISSN: 0892-6638, DOI: 10.1096/fasebj.2019.33.1_supplement.680.15 [A] 1-29 * p. 680.15 *

DOI:   http://dx.doi.org/10.1096/fasebj.2019.33.1_supplement.680.15
by applicantUS5747654
 US4816567
 CN1259962
 CN106967172
   MA LI, CHINESE JOURNAL OF BIRTH HEALTH AND HEREDITY, vol. 24, no. 5, 2016, pages 146 - 148
   ROSKOSKI R JR. ET AL., CRIT REV ONCOL HEMATOL, vol. 62, no. 3, 2007, pages 179 - 213 [A] 1-29 * pp. 1230-1235 *
   TAKAHASHI T ET AL., ONCOGENE, vol. 18, no. 13, 1999, pages 2221 - 2230 [A] 1-29 * p. 680.15 *
   DONG HONGCHAO ET AL., JOURNAL OF MODERN ONCOLOGY, vol. 22, no. 9, September 2014 (2014-09-01), pages 2231 - 3
   HOMET M. B.PARISI G. ET AL.: "Anti-PD-1 Therapy in Melanoma", SEMIN ONCOL., vol. 42, no. 3, 2015, pages 466 - 473
   HELD S.A.HEINE A. ET AL.: "Advances in immunology of biliary muscular tissue CML", CURR. CANCER DRUG TARGETS, vol. 13, no. 7, 2013, pages 768 - 74
   JOYCE F. LIU ET AL., JAMA ONCOL., vol. 5, no. 12, 2019, pages 1731 - 1738
   MANEGOLD C ET AL., J THORAC ONCOL., vol. 12, no. 2, February 2017 (2017-02-01), pages 194 - 207
   DUDEK AZ ET AL., J CLIN ONCOL., vol. 36, 2018
   STEIN S ET AL., J CLIN ONCOL, vol. 36, 2018
   BENDELL JC ET AL., AMERICAN SOCIETY OF CLINICAL ONCOLOGY; MAY 29-JUNE 2, 2015; CHICAGO, IL, 2015
   HOCHSTER HS ET AL., AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL CANCERS SYMPOSIUM; JANUARY 19-21, 2017; SAN FRANCISCO, CA, 2017
   YUKINORI OZAKI ET AL.: "AACR", CANCER RES, vol. 80, no. 4, 2020
   SCHERPEREEL A ET AL., LANCET ONCOL., vol. 20, no. 2, 2019, pages 1109 - 1123
   KRISHNANSU S. ET AL., N ENGL J MED, vol. 370, 2014, pages 734 - 743
   ANTONARAKIS ES ET AL., J CLIN ONCOL., vol. 38, no. 5, 10 February 2020 (2020-02-10), pages 395 - 405
   JOAQUIM BELLMUNT ET AL., N ENGL J MED, vol. 376, 2017, pages 1015 - 1026
   KATO K ET AL., LANCET ONCOL, vol. 20, no. 11, 2019, pages 1506 - 17
   LORD CJASHWORTH A, SCIENCE, vol. 355, no. 6330, 2017, pages 1152 - 1158
   TURNER NC., N ENGL J MED., vol. 377, no. 25, 2017, pages 2490 - 2492
   J. MATEO ET AL., ANN ONCOL., vol. 30, no. 9, 1 September 2019 (2019-09-01), pages 1437 - 1447
   MIRZA MR ET AL., N ENGL J MED, vol. 375, no. 22, 2016, pages 2154 - 2164
   MULLER DKONTERMANN RE: "Bispecific antibodies for cancer immunotherapy: current perspectives", BIODRUGS, vol. 24, 2010, pages 89 - 98, XP009164507, DOI: 10.2165/11530960-000000000-00000

DOI:   http://dx.doi.org/10.2165/11530960-000000000-00000
   COLOMA M. J.MORRISON S. L.: "Design and production of novel tetravalent bispecific antibodies", NAT BIOTECHNOL., vol. 15, 1997, pages 159 - 163, XP000647731, DOI: 10.1038/nbt0297-159

DOI:   http://dx.doi.org/10.1038/nbt0297-159
   MILLER B. R.DEMAREST S. J. ET AL., PROTEIN ENG DES SEL, vol. 23, 2010, pages 549 - 57
   FITZGERALD JLUGOVSKOY A, MABS, vol. 3, 2011, pages 299 - 309
   MATEO J ET AL., ANN ONCOL., vol. 30, no. 9, 2019, pages 1437 - 1447
   JIAO S ET AL., CLIN CANCER RES., vol. 23, no. 14, 2017, pages 3711 - 3720
   RAJAGOPAL ET AL., PROT. ENGIN., vol. 10, 1997, pages 1453 - 1459
   REITER ET AL., NAT. BIOTECHNOL., vol. 14, 1996, pages 1239 - 1245
   REITER ET AL., PROTEIN ENGINEERING, vol. 8, 1995, pages 1323 - 1331
   WEBBER ET AL., MOLECULAR IMMUNOLOGY, vol. 32, 1995, pages 249 - 258
   REITER ET AL., IMMUNITY, vol. 2, 1995, pages 281 - 287
   REITER ET AL., JBC, vol. 269, 1994, pages 18327 - 18331
   REITER ET AL., INTER. J. OF CANCER, vol. 58, 1994, pages 142 - 149
   REITER ET AL., CANCER RES., vol. 54, 1994, pages 2714 - 2718
   CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 3242
   EHRENMANN, FRANCOISQUENTIN KAASMARIE-PAULE LEFRANC: "IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF.", NUCLEIC ACIDS RESEARCH, vol. 38, 2009, pages D301 - D307, XP055247165, DOI: 10.1093/nar/gkp946

DOI:   http://dx.doi.org/10.1093/nar/gkp946
   CHOTHIA ET AL., NATURE, vol. 341, 1989, pages 544 - 546
   "Fundamental Immunology", 1989, RAVEN PRESS
   BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
   HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
   HOLLIGER P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
   ALFTHAN ET AL., PROTEIN ENG, vol. 8, 1995, pages 725 - 731
   CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106
   HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061
   KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
   ROOVERS ET AL., CANCER IMMUNOL, 2001
   POLJAK R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123
   KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
   MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
   JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
   REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
   PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
   CLARK, IMMUNOL. TODAY, vol. 21, 2000, pages 397 - 402
   "Epitope Mapping Protocols", METHODS IN MOLECULAR BIOLOGY, vol. 66, 1996
   "Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
   ACIERNO ET AL.: "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies", J MOL BIOL., vol. 374, no. 1, 2007, pages 130 - 46, XP022310713, DOI: 10.1016/j.jmb.2007.09.005

DOI:   http://dx.doi.org/10.1016/j.jmb.2007.09.005
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.